Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $33.44M (cash outflow) fell 22.8% year over year, ahead of the -107.7% change in trailing-twelve-month net income. Sequentially, it rose 1.8% from the prior quarter. Over 3 fiscal years it compounded at -1.2% a year.

Context

  • Net income amounted to 10773.5% of revenue in FY2025, down 833012.5 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$144.61M (+3.3%) for the fiscal year ending Dec 2026, a step up from the -108.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$33.44M+1.8% QoQ
Last fiscal yearDec 2025
-$140.06M-108.3% YoY
LTMMar 2026
-$130.19M-107.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.8%+24.7%+47.5 pp
1 year-108.3%+3.3%+111.6 pp
3-year CAGR-1.2%-22.6%-21.4 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(140.06M) USD
Year-over-year change
-108.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -107.7% is the lowest of 7, against a peer median of +42.5%.
  • Net income amounts to 10014.2% of revenue for INBX, versus a peer median of 699.1%.
INBX Competitors
Net Income for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$309.06M USD+37.6%+32.1%275948.2%
GENBGenerate Biomedicines, Inc.FY2025$222.97M USD+22.9%—699.1%
IMTXImmatics N.V.LTM Mar 2026€217.14M EUR+906.0%—582.2%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$130.19M USD-107.7%-1.2%10014.2%
ABSIAbsci CorporationLTM Mar 2026$118.44M USD+10.2%+3.2%6450.8%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$115.3M USD+96.5%+1220.8%—
JANXJanux Therapeutics, Inc.LTM Mar 2026$114.48M USD+47.3%+21.7%529.7%
Peer median (excluding INBX) —+42.5%+26.9%699.1%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(81.77M)(145.23M)(239.73M)1.69B(140.06M)
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
Deferred Income Tax(9K)0000
Stock-Based Compensation15.05M20.45M24.85M58.52M11.14M
Change in Working Capital(17.52M)3.16M15.35M52.05M(7.61M)
Accounts Receivables(167K)130K(521K)381K243K
Inventory(11.03M)0000
Accounts Payables(4.64M)(705K)2.11M17.9M(3.3M)
Other Working Capital(1.67M)3.74M13.76M33.77M(4.56M)
Other Non-Cash Items2.73M5.09M5.03M(1.99B)4.25M
Operating Cash Flow(80.32M)(115.3M)(193.31M)(194.41M)(129.79M)
Capital Expenditures(864K)(686K)(4.59M)(2.6M)(31K)
Acquisitions (Net)55K0003K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(809K)(686K)(4.59M)(2.6M)(28K)
Debt Repayment000099.84M
Common Stock Issued40.2M129.74M201.96M71.68M1.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities83.77M128.81M000
Financing Cash Flow83.77M258.55M201.96M71.68M101.45M
Effect of Forex Changes00000
Net Change in Cash2.64M142.56M4.06M(125.33M)(28.38M)
Free Cash Flow(81.19M)(115.99M)(197.9M)(197.01M)(129.83M)

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.